ad image

Triumvira Immunologics

1 / 1
Triumvira Immunologics Inc.
Clinical Trials

Triumvira Immunologics Announces Publication Demonstrating the Safety and Efficacy of TAC T Cells Targeting Claudin 18.2

Triumvira Immunologics Inc.

PR-10-24-NI-47Oct 16, 2024
What do you see as the most significant regulatory decision or guidance on the horizon for 2024 (or beyond)?
Roundtable

What do you see as the most significant regulatory decision or guidance on the horizon for 2024 (or beyond)?

Pharma's Almanac

PAO-12-23-RT-02Dec 15, 2023
How Is Your Organization Currently Leveraging Real-World Data/Evidence and What Uses Do You Anticipate in the Future?
Real-World Data

How Is Your Organization Currently Leveraging Real-World Data/Evidence and What Uses Do You Anticipate in the Future?

Pharma's Almanac

PAO-09-23-RT-01Sep 15, 2023
Triumvira Immunologics Inc.
Financing

Bayer and Northpond Ventures Lead USD $55 Million Series A Financing Round for Triumvira Immunologics

Triumvira Immunologics Inc.

PR-M08-20-NI-45Aug 28, 2020
1 / 1